Concerns settled, share buybacks could flow via exchanges again

While the article doesn't directly mention the pharma sector, a more flexible buyback mechanism could benefit cash-rich pharma companies looking to optimize capital structure or boost EPS. The broader market backdrop shows some resilience in pharma stocks amidst geopolitical tensions.

Monitor pharma companies with strong balance sheets and consistent profitability for potential buyback announcements, which could act as a positive catalyst. Consider long positions in fundamentally strong pharma stocks.

For Indian markets, the practical takeaway is that this story carries a bullish read rather than a generic headline. Traders should judge it by actual market follow-through, not by narrative intensity alone.

Watch whether the market validates this read through price action, volume, and breadth. If the headline matters, the signal should show up in execution, not just in commentary.

• •SEBI is proposing to bring back share buybacks via stock exchanges, reversing a decision made a year ago.
• •New tax rules have resolved earlier concerns about fairness and tax distortions.
• •Public shareholders will now be taxed on actual capital gains, similar to market sales.
• •The change aims to ensure equal participation for all shareholders.
• •Risk flag: Regulatory changes in the pharma sector (e.g., USFDA actions) could still outweigh buyback benefits.